Proven
neurotechnology
built for the
real world
Control Bionics delivers objective, non-invasive neural-signal technology, proven in clinical environments, and built to scale across performance, rehabilitation, medical, research, and assistive communication.
Proven
neurotechnology
built for the
real world
Control Bionics delivers objective, non-invasive neural-signal technology, proven in clinical environments, and built to scale across performance, rehabilitation, medical, research, and assistive communication.
Capability
From signal to actionable insight
The Control Bionics neural-signal platform captures physiological data with medical-grade precision and converts it into measurable, decision-ready outcomes. Built for deployment across clinical, research, and performance environments — and validated where it counts.
Signal acquisition and processing
Real-time analysis and validation
Clinical integration and reporting
Technology
The platform serves distinct markets with precision and measurable outcomes. One underlying technology - four applications.
A platform built for clinical deployment
Medical-grade signal processing meets real-world clinical environments. Designed for integration, validation, and measurable outcomes.
Non-invasive neural signal capture
Physiological data without surgical intervention or implantation. Validated for use in complex clinical environments.
Regulatory pathway established
Cleared for clinical use with ongoing validation across multiple applications — FDA, TGA, and CE registered.
Outcome-focused architecture
Platform designed to deliver decision-ready insights, not only raw data. Built to integrate into clinical and research workflows.
Evidence from clinical and research deployment
Control Bionics technology is validated through research, clinical trials, and real-world deployment across rehabilitation, performance, and research settings.
1,000s of users
Trusted by individuals, clinicians, and organisations across four markets
Government and privately funded
Approved for funding through Medicare, Medicaid, NDIS, and private insurance pathways.
100%
Non-invasive signal acquisition
3 Regulatory clearances
(FDA, TGA, CE)
Latest from our platform
Research, clinical validation and platform developments.
International Impact: A Message of Hope
Kiichi Otsuka, an ALS patient from Japan, lost his ability to speak due to a tracheotomy. However, his life took a positive turn when he discovered NeuroNode.
New Recorded Course: Eye Gaze 101
The Eye Gaze 101 course, hosted by Kristin Whitfield, is now available online for you to view at anytime! Designed to discuss the basics of eye gaze technology with clinicians, teachers, and family members. Despite being an important means of access for many...
Grid Three Update: QWERTY Format Added to Scanning Interface
We're thrilled to announce that the popular scanning interfaces for kids, young adults, and adults have received an update that will make communication even easier and more efficient. The "16 Location High Contrast Scanning Kids and Young Adults", "16 Location...
The worldwide launch of DROVE World First Autonomous Wheelchair Module Launch
The launch of DROVE, the world’s first autonomous driving wheelchair module created by Control Bionics, was an exciting event that garnered a lot of press and attention. The keynote speaker, Jeremy Steele, the CEO of Control Bionics, introduced Drove to the world and explained how it was created to give users the ability to independently traverse a home environment.
Select your path to neural-signal insights and outcomes
Explore how the platform integrates into clinical workflows and delivers decision-ready outcomes.
Learn more
Discover how researchers are using real-time neural data to power breakthrough studies.
LearnNDIS-registered provider
Control Bionics is a registered NDIS provider. Eligible participants can access our assistive communication devices and neurotechnology solutions through their NDIS plan.